Early detection & personalized management of dementia & Alzheimer’s disease in elderly patients

Alzheimer's disease (AD) is sixth most common cause of death & the primary cause of dementia in the elderly. AD places a heavy financial strain on society and presents unique difficulties for parents and families that are affected. As the population ages, the issue will most likely become much worse soon. As of right now, there is no drug that can either cure or prevent the sickness. Alzheimer's disease (AD)-related dementia is one of primary causes of debilitation in elderly (over 65); early-stage AD cases, which make up around 2-5% of all cases, are also recognized. The improper classification of patients according to genetic variants and the lack of corroborating biomarker data for the pre-symptomatic registry seem to be additional factors causing this failure. Finally, the use of electronic health records (EHR) offers the chance to appropriately combine genetic, clinical, and biomarker data. In an effort to apply precision medicine to a greater variety of illnesses, governments everywhere are starting to put these initiatives into action. It is essential to diagnose Alzheimer's disease (AD) early in order to improve patient outcomes & enable timely treatment. Numerous strategies, such as artificial intelligence & enhanced imaging methods, are being investigated to improve medical accuracy & usability. Early identification has numerous benefits, but in order to improve outcomes for people who are at risk of Alzheimer's disease.